Sirenade: Disentangling Alzheimer's

Most companies developing therapies for Alzheimer's disease focus on the development of drugs and vaccines to prevent or to destroy the plaques that typically accumulate in the brains of AD patients. Sirenade Pharmaceuticals AG believes that this strategy must be complemented with a treatment directed at the neurofibrillary tangles also associated with AD. The company claims it has a substance that does the trick.

Scientists have suspected for a few years that therapeutic intervention in AD should target both beta amyloid plaques and tau protein, which forms the neurofibrillary tangles (NFTs). ...